ArticleInternational journal of women's health2026
Gut Microbiota and SCFA Changes After Alendronate-Calcitriol Therapy in Postmenopausal Osteoporosis.
Article in International journal of women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis (PMO) is driven primarily by estrogen deficiency, and gut microbiota-derived metabolites may participate in bone remodeling. The intestinal effects of conventional anti-osteoporosis therapy remain unclear. We investigated gut microbial and short-chain fatty acid (SCFA) changes associated with alendronate-calcitriol therapy in PMO. Methods: Forty-one postmenopausal women were enrolled, including 21 healthy controls and 20 patients with PMO. PMO patients received oral alendronate plus calcitriol for six months, with paired fecal samples collected before and after treatment. Shotgun metagenomic sequencing was used to assess microbial taxonomy, KEGG pathways, and CAZy profiles. Fecal SCFAs were quantified by gas chromatography-mass spectrometry. Results: After treatment, lumbar spine BMD T-score improved from -2.98 to -2.65, and femoral neck BMD T-score increased from -2.40 to -2.12, and all measured bone turnover markers (BALP, TRACP-5b, PINP and osteocalcin) decreased significantly (P < 0.05). Global microbial diversity did not differ significantly among groups, but treatment was accompanied by shifts in specific taxa. Conclusion: Alendronate-calcitriol therapy was associated with improved bone metabolism and treatment-associated shifts in gut microbial composition, microbial functional potential, and propionate-related SCFA profiles. These findings provide preliminary evidence for microecological changes accompanying conventional PMO therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.